Cellosaurus logo
expasy logo

Cellosaurus 451Lu (CVCL_6357)

[Text version]
Cell line name 451Lu
Synonyms 451LU; 451-LU; WM 451-Lu; WM-451Lu; WM-451LU; WM451Lu; WM451; WC00059; LU451; Lu451; EST81
Accession CVCL_6357
Resource Identification Initiative To cite this cell line use: 451Lu (RRID:CVCL_6357)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: Wistar Institute melanoma cell line collection.
Population: Caucasian.
Characteristics: Metastatic. Established from the lung of a nude mouse after 4 sequential passages of the parent cell line (PubMed=2156614).
Doubling time: 72 hours (PubMed=2253310).
Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 10->10,13, D5S818: 11,12->12, D7S820: 9,10->10 and FGA: 21->21,25.
Derived from site: Metastatic; Arm, skin; UBERON=UBERON_0002427.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=18632627; PubMed=21156289; PubMed=23851445; Cosmic-CLP=1287706; DepMap=ACH-001002; Wistar).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP=1287706; DepMap=ACH-001002).
  • Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=17260012; PubMed=21156289; PubMed=23851445; Cosmic-CLP=1287706; DepMap=ACH-001002).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*24:02,24:02
HLA-BB*07:02,07:02
Class II
HLA-DPDPB1*06:01,06:01
HLA-DQDQB1*06:04,06:04
HLA-DRDRB1*13:01,13:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American1.32
East Asian, North0.06
East Asian, South0.98
South Asian0.7
European, North67.32
European, South29.61
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_7928 (WM164)
Children:
CVCL_AP83 (451Lu-BR)CVCL_DG54 (451Lu-MR)
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2813; Cosmic-CLP=1287706; ESTDAB=ESTDAB-081; PubMed=25056119; Wistar

Markers:
AmelogeninX
CSF1PO12
D2S133818,19
D3S135818
D5S81812
D7S8209,10 (ATCC=CRL-2813; ESTDAB=ESTDAB-081)
10 (Cosmic-CLP=1287706; Wistar)
D8S117913,14
D13S31711
D16S53913
D18S5110,13
D19S43313
D21S1128,31.2
FGA21,25
TH019
TPOX8,10
vWA14,15

Run an STR similarity search on this cell line
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
Publications

PubMed=2918552; DOI=10.1093/jnci/81.6.440
Iliopoulos D., Ernst C.S., Steplewski Z., Jambrosic J.A., Rodeck U., Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
J. Natl. Cancer Inst. 81:440-444(1989)

PubMed=2156614
Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A.H., Baird J., Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.
In vitro properties of human melanoma cells metastatic in nude mice.
Cancer Res. 50:2296-2302(1990)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=8342600; PMCID=PMC1887031
Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A., Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235; PMCID=PMC2615688
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431; PMCID=PMC2651569
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131
Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T., Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
Cancer Immunol. Immunother. 58:1507-1515(2009)

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023; PMCID=PMC3026446
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)

PubMed=23285177; DOI=10.1371/journal.pone.0052760; PMCID=PMC3532357
Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J., Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H., Schuchter L.M., Clark D.P.
Functional profiling of live melanoma samples using a novel automated platform.
PLoS ONE 7:E52760-E52760(2012)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023; PMCID=PMC3956616
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T; PMCID=PMC4167745
Watson I.R., Li L.-R., Cabeceiras P.K., Mahdavi M., Gutschner T., Genovese G., Wang G.-C., Fang Z.-N., Tepper J.M., Stemke-Hale K., Tsai K.Y., Davies M.A., Mills G.B., Chin L.
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Cancer Res. 74:4845-4852(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2813 - Discontinued
Coriell; WC00059 - Discontinued
Rockland; 451Lu-01-0001
Cell line databases/resources CLO; CLO_0001373
cancercelllines; CVCL_6357
Cell_Model_Passport; SIDM01240
Cosmic-CLP; 1287706
DepMap; ACH-001002
ESTDAB; ESTDAB-081
Anatomy/cell type resources BTO; BTO:0003710
Biological sample resources BioSample; SAMN03471798
Chemistry resources ChEMBL-Cells; CHEMBL4802054
GDSC; 1287706
PharmacoDB; 451Lu_17_2019
PubChem_Cell_line; CVCL_6357
Encyclopedic resources Wikidata; Q54603178
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM156019
GEO; GSM188238
GEO; GSM188268
GEO; GSM188327
GEO; GSM555137
GEO; GSM555187
GEO; GSM952579
GEO; GSM1199178
GEO; GSM1669568
Polymorphism and mutation databases Cosmic; 686411
Cosmic; 1047656
Cosmic; 1155281
Cosmic; 1155568
Cosmic; 1187587
Cosmic; 1303027
Cosmic; 2163808
Cosmic; 2230114
IARC_TP53; 26083
Progenetix; CVCL_6357
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number39